Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naive individuals from india

AIDS Research and Human Retroviruses

Volumn 25, Issue 5, 2009, Pages 521-523

  Sen, Sourav ^a   Tripathy, S P ^b   Sahni, A K ^c   Gupta, R M ^a   Kapila, K ^a   Chopra, G S ^a   Chimanpure, Vaishali M ^b   Patil, Ajit A ^b   Paranjape, R S ^b  

^a ARMED FORCES MEDICAL COLLEGE   (India)

^b NATIONAL AIDS RESEARCH INSTITUTE   (India)

^c ARMY HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE; GLYCOPROTEIN GP 41; VIRUS DNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INDIA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; INDIA; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PROVIRUSES; SEQUENCE ANALYSIS, DNA;

EID: 66149184531     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0244     Document Type: Article

References (17)

1. Sista PR, Melby T, Davison D, et al.: Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004;18:1787-1794.
2. Holguín A, RamÌrez de Arellano E, and Soriano V: Amino cid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. AIDS Res Hum Retroviruses 2007;23(9):1067-1074.
3. Ramakrishnan R, Mehta R, Sundaravaradan V, Davis T, and Ahmad N: Characterization of HIV-1 envelope gp41 genetic diversity and functional domains following perinatal transmission. Retrovirology 2006;3:42.
4. Pieniazek D, Yang C, and Lal RB: Phylogenetic analysis of gp41 envelope of HIV-1 groups M, N, and O strains provides an alternate region for subtype determination. In Korber B, Hahn BH, and Foley B (eds.), Human Retrovirus and AIDS. Los Alamos National Laboratory, Los Alamos, NM, 1998: pp. III 112-III 117.
5. Rimsky LT, Shugars DC, and Matthews TJ: Determinants of HIV- 1 resistance to gp41-derived inhibitory peptide. J Virol 1998;72:986-993.
6. Wei X, Decker JM, Liu H, et al.: Emergence of resistant HIV-1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896-1905.
7. Chinnadurai R, Münch J, and Kirchhoff F: Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors. AIDS 2005;19(13)2:1401-1405.
8. Nameki D, Kodama E, Ikeuchi M, et al.: Mutations conferring resistance to HIV-1 fusion inhibitors are restricted by gp41 and Rev responsive element functions. J Virol 2005;79: 764-770.
9. Menzo S, Castagna A, Monachetti A, et al.: Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. New Microbiol 2004;27: 51-61.
10. Aquaro S, D'Arrigo R, Svicher V, et a.l: Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother 2006;58:714-722.
11. Lu J, Deeks SG, Hoh R, et al.: Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis. J Acquir Immune Defic Syndr 2006;43:60-64.
12. Melby T, Sista P, DeMasi R, et al.: Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses 2006;22:375-385.
13. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, and Derdeyn CA: Determinants of HIV-1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004;78:7582-7589.
14. Xu L, Pozniak A, Wildfire A, et al.: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005;49:1113-1119.
15. Carmona R, Perez-Alvarez L, Munoz M, et al.: Natural resistance associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 näive patients. J Clin Virol 2005;32:248-253.
16. Mink M, Mosier SM, Janumpalli S, et al.: Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 2005; 79(19):12447-12454.
17. + cell count, despite virological failure. J Infect Dis 2008;197:1408-1418.